<DOC>
	<DOCNO>NCT00022737</DOCNO>
	<brief_summary>This phase II trial study well combination chemotherapy without donor peripheral stem cell transplant work treat child acute lymphoblastic leukemia . Giving combination chemotherapy donor peripheral stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Peripheral Stem Cell Transplant Treating Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine feasibility treatment intensified chemotherapy , term toxicity patient accrual , child high-risk acute lymphoblastic leukemia . II . Determine feasibility efficacy follow intensified chemotherapy allogeneic hematopoietic stem cell transplantation patient HLA-matched related donor . III . Determine toxicity imatinib mesylate combination intensify chemotherapy Philadelphia chromosome-positive patient . IV . Determine event-free survival patient treat regimen . V. Determine whether minimal residual disease ( MDR ) induction therapy prior intensification therapy predict relapse patient . VI . Determine whether MDR intensification prognostically significant . VII . Determine whether gene expression pattern predict disease recurrence response imatinib mesylate . OUTLINE : This multicenter study . This also dose-escalation study imatinib mesylate Philadelphia chromosome-positive ( Ph+ ) patient . Patients stratify accord Philadelphia chromosome ( Ph ) status ( Ph-positive v Ph-negative indeterminate ) , hypodiploidy ( yes v ) , MLL translocation ( 11q23 ) AND slow early response prior induction therapy ( yes v ) , fail prior induction therapy ( yes v ) . Cohorts 8-12 Ph+ patient receive escalate dos imatinib mesylate , accord guideline treatment block study , maximum tolerate dose ( MTD ) treatment combination determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . An additional 35 patient treated MTD . CONSOLIDATION BLOCK 1 : Patients receive etoposide IV 1 hour follow ifosfamide IV 1.5 hour day 1-5 . Patients also receive methotrexate intrathecally day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) day 6-15 blood count recover . Patients CNS 2/3 diagnosis also receive intrathecal triple therapy comprise methotrexate , hydrocortisone , cytarabine ( ITT ) day 8 15 . Ph+ patient cohorts 3 , 4 , 5 receive oral imatinib mesylate day 1-21 . Within 4 day start consolidation therapy , patient biopsy-proven testicular leukemia undergo radiotherapy daily 12 day . CONSOLIDATION BLOCK 2 : Patients receive high-dose methotrexate IV 24 hour ITT day 1 follow high-dose cytarabine IV 3 hour , every 12 hour day 2 3 . Patients also receive leucovorin calcium IV orally every 6 hour 3 dos begin day 2 , G-CSF SC day 4-13 blood count recover . Ph+ patient cohorts 2 , 3 , 4 , 5 receive oral imatinib mesylate consolidation block 1 . Patients undergo allogeneic hematopoietic stem cell transplantation ( HSCT ) proceed preparative chemotherapy . All patient proceed reinduction block 1 . REINDUCTION BLOCK 1 : Patients receive vincristine IV day 1 , 8 , 15 ; daunorubicin IV day 1 2 ; cyclophosphamide IV 30 minute , every 12 hour day 3 4 ; pegaspargase intramuscularly ( IM ) day 4 ; ITT day 1 15 . Patients also receive oral dexamethasone twice daily day 1-7 15-21 G-CSF SC day 5-14 blood count recover . Ph+ patient cohorts 2 , 4 , 5 receive imatinib mesylate consolidation block 1 . INTENSIFICATION BLOCK 1 : Patients receive high-dose methotrexate IV 24 hour day 1 15 ITT day 1 22 . Patients also receive leucovorin calcium IV orally every 6 hour 3 dos begin day 2 16 . Patients receive etoposide IV 2 hour follow cyclophosphamide IV 30 minute day 22-24 ; G-CSF SC day 27-36 blood count recover ; high-dose cytarabine IV 3 hour , every 12 hour day 43 44 ; asparaginase IM day 44 . Ph+ patient cohorts 1 4 receive oral imatinib mesylate day 43-63 , patient cohort 5 receive oral imatinib mesylate day 1-56 . REINDUCTION BLOCK 2 : Patients receive vincristine , daunorubicin , cyclophosphamide , pegaspargase , dexamethasone , G-CSF reinduction block 1 . Patients also receive ITT day 1 15 . Ph+ patient receive imatinib mesylate reinduction block 1 . INTENSIFICATION BLOCK 2 : Patients receive methotrexate , leucovorin calcium , etoposide , cyclophosphamide , filgrastim , cytarabine , asparaginase intensification block 1 . Ph+ patient receive imatinib mesylate intensification block 1 . MAINTENANCE 1 : Patients receive high-dose methotrexate IV leucovorin calcium consolidation block 2 . Patients also receive ITT vincristine IV day 1 29 ; oral dexamethasone twice daily day 1-5 29-33 ; oral methotrexate day 8 , 15 , 22 ; oral mercaptopurine day 8-28 ; etoposide IV 2 hour follow cyclophosphamide IV 30 minute day 29-33 ; G-CSF SC day 34-43 . Ph+ patient cohorts 1-4 receive oral imatinib mesylate day 29-49 patient cohort 5 receive oral imatinib mesylate day 1-56 . Treatment repeat every 8 week 4 course absence disease progression unacceptable toxicity . MAINTENANCE 2 : Patients receive vincristine dexamethasone maintenance 1 . Beginning day 1 , patient undergo cranial radiotherapy daily , 5 day week , approximately 2 week . Patients also receive oral methotrexate day 8 , 15 , 22 , 29 , 36 , 43 , 50 oral mercaptopurine day 11-56 . Ph+ patient cohorts 1-4 receive oral imatinib mesylate day 1-21 29-49 , patient cohort 5 receive oral imatinib mesylate day 1-56 . MAINTENANCE 3 : Patients receive vincristine dexamethasone maintenance 2 . Patients also receive oral methotrexate day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 ; oral mercaptopurine day 1-56 . Ph+ patient receive imatinib mesylate maintenance 2 . Treatment repeat every 8 week 7 course ( 12 course total maintenance 1 , 2 , 3 ) absence disease progression unacceptable toxicity . Patients may undergo allogeneic HSCT consolidation block 2 available HLA-DR match HLA-A -B match 1 antigen mismatch relative donor . Patients CNS leukemia undergo cranial radiotherapy 3 time daily day -10 -8 . All patient undergo radiotherapy twice daily day -7 -5 receive etoposide IV day -4 cyclophosphamide IV day -3 -2 . Patients undergo allogeneic bone marrow , peripheral blood stem cell , umbilical cord blood transplantation day 0 . Patients receive cyclosporine IV begin day -1 continue every 12 hour , switch oral administration possible , day 60 tapering thereafter . Patients also receive methotrexate day 1 , 3 , 6 . Beginning 16-24 week transplantation , Ph+ patient receive oral imatinib mesylate daily 24 week . Patients follow every 4-8 week 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . Patients undergo HSCT follow weekly first year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Diagnosis acute lymphoblastic leukemia Received prior frontline therapy Pediatric Oncology Group ( POG ) , Children 's Cancer Group ( CCG ) , Central Oncology Group ( COG ) study Received induction therapy comprise vincristine , asparaginase , prednisone/dexamethasone , daunorubicin CCG , POG , COG protocols M1 M2 bone marrow status frontline induction therapy present least 1of follow : Philadelphia chromosome positive ( Ph+ ) ( 9 ; 22 ) ( q34 ; q11 ) cytogenetics fluorescence situ hybridization bcrabl fusion transcript reverse transcription polymerase chain reaction Hypodiploid le 44 chromosome and/or DNA index less than0.81 MLL translocation ( 11q23 ) cytogenetics slow early response ( SER ) induction therapy , define least 5 % blast day 15 induction and/or least .1 % minimal residual disease ( MRD ) induction therapy Failed achieve remission frontline induction therapy M3 bone marrow status ( great 25 % blast ) induction therapy M2 bone marrow status ( 525 % blast ) least 1 % MRD induction therapy M2 M3or least 1 % MRD consolidation therapy ( CCG study ) extend induction therapy ( POG COG study ) See Disease Characteristics Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception See Disease Characteristics See Disease Characteristics No concurrent prophylactic cranial radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>